Literature DB >> 24103327

Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.

G Michael Felker1, Mona Fiuzat, Vivian Thompson, Linda K Shaw, Megan L Neely, Kirkwood F Adams, David J Whellan, Mark P Donahue, Tariq Ahmad, Dalane W Kitzman, Ileana L Piña, Faiez Zannad, William E Kraus, Christopher M O'Connor.   

Abstract

BACKGROUND: ST2 is involved in cardioprotective signaling in the myocardium and has been identified as a potentially promising biomarker in heart failure (HF). We evaluated ST2 levels and their association with functional capacity and long-term clinical outcomes in a cohort of ambulatory patients with HF enrolled in the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study-a multicenter, randomized study of exercise training in HF. METHODS AND
RESULTS: HF-ACTION randomized 2331 patients with left ventricular ejection fraction <0.35 and New York Heart Association class II to IV HF to either exercise training or usual care. ST2 was analyzed in a subset of 910 patients with evaluable plasma samples. Correlations and Cox models were used to assess the relationship among ST2, functional capacity, and long-term outcomes. The median baseline ST2 level was 23.7 ng/mL (interquartile range, 18.6-31.8). ST2 was modestly associated with measures of functional capacity. In univariable analysis, ST2 was significantly associated with death or hospitalization (hazard ratio, 1.48; P<0.0001), cardiovascular death or HF hospitalization (hazard ratio, 2.14; P<0.0001), and all-cause mortality (hazard ratio, 2.33; P<0.0001; all hazard ratios for log2 ng/mL). In multivariable models, ST2 remained independently associated with outcomes after adjustment for clinical variables and amino-terminal pro-B-type natriuretic peptide. However, ST2 did not add significantly to reclassification of risk as assessed by changes in the C statistic, net reclassification improvement, and integrated discrimination improvement.
CONCLUSIONS: ST2 was modestly associated with functional capacity and was significantly associated with outcomes in a well-treated cohort of ambulatory patients with HF although it did not significantly affect reclassification of risk. CLINICAL TRIAL INFORMATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00047437.

Entities:  

Keywords:  biomarkers; heart failure; prognosis

Mesh:

Substances:

Year:  2013        PMID: 24103327      PMCID: PMC4188425          DOI: 10.1161/CIRCHEARTFAILURE.113.000207

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  24 in total

1.  Establishment of reference intervals for soluble ST2 from a United States population.

Authors:  Jun Lu; James V Snider; David G Grenache
Journal:  Clin Chim Acta       Date:  2010-07-21       Impact factor: 3.786

Review 2.  Biomarkers in heart failure.

Authors:  Eugene Braunwald
Journal:  N Engl J Med       Date:  2008-05-15       Impact factor: 91.245

3.  High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure.

Authors:  Bonnie Ky; Benjamin French; Kristin McCloskey; J Eduardo Rame; Erin McIntosh; Puja Shahi; Daniel L Dries; W H Wilson Tang; Alan H B Wu; James C Fang; Rebecca Boxer; Nancy K Sweitzer; Wayne C Levy; Lee R Goldberg; Mariell Jessup; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2010-12-22       Impact factor: 8.790

4.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.

Authors:  Robin A P Weir; Ashley M Miller; Grace E J Murphy; Suzanne Clements; Tracey Steedman; John M C Connell; Iain B McInnes; Henry J Dargie; John J V McMurray
Journal:  J Am Coll Cardiol       Date:  2010-01-19       Impact factor: 24.094

5.  Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.

Authors:  Inder S Anand; Tibor Kempf; Thomas S Rector; Heike Tapken; Tim Allhoff; Franziska Jantzen; Michael Kuskowski; Jay N Cohn; Helmut Drexler; Kai C Wollert
Journal:  Circulation       Date:  2010-09-20       Impact factor: 29.690

6.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction.

Authors:  Domingo A Pascual-Figal; Jordi Ordoñez-Llanos; Pedro L Tornel; Rafael Vázquez; Teresa Puig; Mariano Valdés; Juan Cinca; Antoni Bayes de Luna; Antoni Bayes-Genis
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

7.  Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.

Authors:  Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña
Journal:  JAMA       Date:  2009-04-08       Impact factor: 56.272

8.  Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction.

Authors:  Marc S Sabatine; David A Morrow; Luke J Higgins; Catherine MacGillivray; Wei Guo; Christophe Bode; Nader Rifai; Christopher P Cannon; Robert E Gerszten; Richard T Lee
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

9.  Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling.

Authors:  Kenjiro Seki; Shoji Sanada; Anastacia Y Kudinova; Matthew L Steinhauser; Vandna Handa; Joseph Gannon; Richard T Lee
Journal:  Circ Heart Fail       Date:  2009-09-22       Impact factor: 8.790

Review 10.  The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease.

Authors:  Ashley M Miller; Foo Y Liew
Journal:  Pharmacol Ther       Date:  2011-02-26       Impact factor: 12.310

View more
  42 in total

1.  Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study.

Authors:  Abhinav Sharma; Susanna R Stevens; Joseph Lucas; Mona Fiuzat; Kirkwood F Adams; David J Whellan; Mark P Donahue; Dalane W Kitzman; Ileana L Piña; Faiez Zannad; William E Kraus; Christopher M O'Connor; G Michael Felker
Journal:  JACC Heart Fail       Date:  2017-10       Impact factor: 12.035

Review 2.  Emerging risk biomarkers in cardiovascular diseases and disorders.

Authors:  Ravi Kant Upadhyay
Journal:  J Lipids       Date:  2015-04-08

3.  Imaging the patient with a new diagnosis of heart failure in the contemporary era.

Authors:  James E Udelson
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

Review 4.  Novel Biomarkers in Heart Failure Beyond Natriuretic Peptides - The Case for Soluble ST2.

Authors:  Antonio J Vallejo-Vaz
Journal:  Eur Cardiol       Date:  2015-07

5.  Serum ST2 and hospitalization rates in Caucasian and African American outpatients with heart failure.

Authors:  Panagiotis Savvoulidis; James V Snider; Sahil Rawal; Alanna A Morris; Javed Butler; Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos
Journal:  Int J Cardiol       Date:  2019-11-06       Impact factor: 4.164

6.  Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure.

Authors:  Tariq Ahmad; Emily C O'Brien; Phillip J Schulte; Susanna R Stevens; Mona Fiuzat; Dalane W Kitzman; Kirkwood F Adams; William E Kraus; Ileana L Piña; Mark P Donahue; Faiez Zannad; David J Whellan; Christopher M O'Connor; G Michael Felker
Journal:  Circ Heart Fail       Date:  2015-06-01       Impact factor: 8.790

Review 7.  Biomarkers in pulmonary arterial hypertension.

Authors:  Julie L Rosenthal; Miriam S Jacob
Journal:  Curr Heart Fail Rep       Date:  2014-12

8.  Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.

Authors:  Hicham Skali; Robert Gerwien; Timothy E Meyer; James V Snider; Scott D Solomon; Craig M Stolen
Journal:  J Cardiovasc Transl Res       Date:  2016-10-31       Impact factor: 4.132

9.  Comparative symptom biochemistry between moderate and advanced heart failure.

Authors:  Christopher S Lee; Quin E Denfeld; Bradley E Aouizerat; Corrine Y Jurgens; Christopher V Chien; Emily Aarons; Jill M Gelow; Shirin O Hiatt; James O Mudd
Journal:  Heart Lung       Date:  2018-10-09       Impact factor: 2.210

Review 10.  Role of Inflammation in Heart Failure.

Authors:  Lily F Shirazi; Joe Bissett; Francesco Romeo; Jawahar L Mehta
Journal:  Curr Atheroscler Rep       Date:  2017-06       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.